Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer’s disease. Lancet 368:387–403
Hardy J (2006) Alzheimer’s disease: the amyloid cascade hypothesis: an update and reappraisal. J Alzheimers Dis 9:151–153
Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297:353–356
O’Brien RJ, Wong PC (2011) Amyloid precursor protein processing and Alzheimer’s disease. Annu Rev Neurosci 34:185–204
Gendron TF, Petrucelli L (2009) The role of tau in neurodegeneration. Mol Neurodegener 4:13. doi:10.1186/1750-1326-4-13
Giannopoulos PF, Joshi YB, Praticò D (2014) Novel lipid signaling pathways in Alzheimer’s disease pathogenesis. Biochem Pharmacol 88:560–564
Di Paolo G, Kim TW (2011) Linking lipids to Alzheimer’s disease: cholesterol and beyond. Nat Rev Neurosci 12:284–296
Verri M, Pastoris O, Dossena M et al (2012) Int J Immunopathol Pharmacol 25:345–353
Francis PT (2005) The interplay of neurotransmitters in Alzheimer’s disease. CNS Spectr 10:6–9
Kaddurah-Daouk R, Zhu H, Sharma S et al (2013) Alterations in metabolic pathways and networks in Alzheimer’s disease. Transl Psychiatry 3:e244. doi:10.1038/tp.2013.18
Noorbakhsh F, Overall CM, Power C (2009) Deciphering complex mechanisms in neurodegenerative diseases: the advent of systems biology. Trends Neurosci 32:88–100
Lausted C, Lee I, Zhou Y et al (2014) Systems approach to neurodegenerative disease biomarker discovery. Annu Rev Pharmacol Toxicol 54:457–481
Morris JK, Honea RA, Vidoni ED et al (2014) Is Alzheimer’s disease a systemic disease? Biochim Biophys Acta 1842:1340–1349
Riviere S, Gillette-Guyonnet S, Andrieu S et al (2002) Cognitive function and caregiver burden: predictive factors for eating behaviour disorders in Alzheimer’s disease. Int J Geriatr Psychiatry 17:950–955
Hampel H, Lista S, Khachaturian ZS (2012) Development of biomarkers to chart all Alzheimer’s disease stages: the royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement 8:312–336
Bensimon A, Heck AJ, Aebersold R (2012) Mass spectrometry based proteomics and network biology. Annu Rev Biochem 81:379–405
Sabido’ E, Selevsek N, Aebersold R (2012) Mass spectrometry based proteomics for systems biology. Curr Opin Biotechnol 23:591–597
Tyers M, Mann M (2003) From genomics to proteomics. Nature 422:193–197
Shevchenko G, Konzer A, Musunuri S et al (2015) Neuroproteomics tools in clinical practice. Biochim Biophys Acta 1854:705–717
Marko-Varga G, Fehniger TE (2004) Proteomics and disease—the challenges for technology and discovery. J Proteome Res 3:167–178
Kim SI, Voshol H, van Oostrum J et al (2004) Neuroproteomics: expression profiling of the brain’s proteomes in health and disease. Neurochem Res 29:1317–1331
Hamacher M, Meyer HE (2005) HUPO Brain Proteome Project: aims and needs in proteomics. Expert Rev Proteomics 2:1–3
Lista S, O’Bryant SE, Blennow K et al (2015) Biomarkers in sporadic and familial Alzheimer’s disease. J Alzheimers Dis 47(2):291–317. doi:10.3233/JAD-143006
Hampel H, Lista S, Teipel SJ et al (2014) Perspective on future role of biological markers in clinical therapy trials of Alzheimer’s disease: a long-range point of view beyond 2020. Biochem Pharmacol 88:426–449
Dubois B, Epelbaum S, Santos A et al (2013) Alzheimer disease: from biomarkers to diagnosis. Rev Neurol (Paris) 169:744–751
Hampel H, Lista S (2013) Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement. J Nutr Health Aging 17:54–63
Hampel H, Lista S (2012) Alzheimer disease: from inherited to sporadic AD-crossing the biomarker bridge. Nat Rev Neurol 8:598–600
Bertram L, Hampel H (2011) The role of genetics for biomarker development in neurodegeneration. Prog Neurobiol 95:501–514
Zetzsche T, Rujescu D, Hardy J et al (2010) Advances and perspectives from genetic research: development of biological markers in Alzheimer’s disease. Expert Rev Mol Diagn 10:667–690
Teipel SJ, Grothe M, Lista S et al (2013) Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease. Med Clin North Am 97:399–424
Ewers M, Sperling RA, Klunk WE et al (2012) Neuroimaging markers for the prediction and early diagnosis of Alzheimer’s disease dementia. Trends Neurosci 34:430–442
Rosén C, Hansson O, Blennow K et al (2013) Fluid biomarkers in Alzheimer’s disease—current concepts. Mol Neurodegener 8:20. doi:10.1186/1750-1326-8-20
Blennow K, Zetterberg H, Fagan AM (2012) Fluid biomarkers in Alzheimer disease. Cold Spring Harb Perspect Med 2:a006221. doi:10.1101/cshperspect.a006221
Blennow K, Dubois B, Fagan AM et al (2015) Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease. Alzheimers Dement 11:58–69
Blennow K, Hampel H, Weiner M et al (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6:131–144
Hampel H, Shen Y, Walsh DM et al (2010) Biological markers of amyloid beta-related mechanisms in Alzheimer’s disease. Exp Neurol 223:334–346
Hampel H, Blennow K, Shaw LM et al (2010) Total and phosphorylated tau protein as biological markers of Alzheimer’s disease. Exp Gerontol 45:30–40
Henriksen K, O’Bryant SE, Hampel H et al (2014) The future of blood-based biomarkers for Alzheimer’s disease. Alzheimers Dement 10:115–131
O’Bryant SE, Gupta V, Henriksen K et al (2015) Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer’s disease research. Alzheimers Dement 11:549–560
Snyder HM, Carrillo MC, Grodstein F et al (2014) Developing novel blood-based biomarkers for Alzheimer’s disease. Alzheimers Dement 10:109–114
Gupta VB, Sundaram R, Martins RN (2013) Multiplex biomarkers in blood. Alzheimers Res Ther 5:31. doi:10.1186/alzrt185
Lista S, Faltraco F, Prvulovic D et al (2013) Blood and plasma-based proteomic biomarker research in Alzheimer’s disease. Prog Neurobiol 101–102:1–17
Edwards M, Balldin VH, Hall J et al (2014) Combining select neuropsychological assessment with blood-based biomarkers to detect mild Alzheimer’s disease: a molecular neuropsychology approach. J Alzheimers Dis 42:635–640
Lista S, Garaci FG, Ewers M et al (2014) CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer’s disease. Alzheimers Dement 10:381–392
Teipel SJ, Sabri O, Grothe M et al (2013) Perspectives for multimodal neurochemical and imaging biomarkers in Alzheimer’s disease. J Alzheimers Dis 33:S329–S347
Lista S, Emanuele E (2011) Role of amyloid β1-42 and neuroimaging biomarkers in Alzheimer’s disease. Biomark Med 5:411–413
Broich K, Weiergräber M, Hampel H (2011) Biomarkers in clinical trials for neurodegenerative diseases: regulatory perspectives and requirements. Prog Neurobiol 95:498–500
Hampel H, Frank R, Broich K et al (2010) Biomarkers for Alzheimer’s disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 9:560–574
Doody RS, Raman R, Farlow M et al (2013) A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med 369:341–350
Salloway S, Sperling R, Fox NC et al (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 37:322–333
Doody RS, Thomas RG, Farlow M et al (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 370:311–321
Karran E, Hardy J (2014) Antiamyloid therapy for Alzheimer’s disease—are we on the right road? N Engl J Med 370:377–378
Brinkmalm A, Portelius E, Öhrfelt A et al (2015) Explorative and targeted neuroproteomics in Alzheimer’s disease. Biochim Biophys Acta 1854:769–778
Aebersold R, Mann M (2003) Mass spectrometry-based proteomics. Nature 422:198–207
Evans C, Noirel J, Ow SY et al (2012) An insight into iTRAQ: where do we stand now? Anal Bioanal Chem 404:1011–1027
Ong SE, Blagoev B, Kratchmarova I et al (2002) Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 1:376–386
Hölttä M, Minthon L, Hansson O et al (2015) An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer’s disease. J Proteome Res 14:654–663
Mattsson N, Zegers I, Andreasson U et al (2012) Reference measurement procedures for Alzheimer’s disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42. Biomark Med 6:409–417
Mann M, Kulak NA, Nagaraj N et al (2013) The coming age of complete, accurate, and ubiquitous proteomes. Mol Cell 49:583–590
Portelius E, Gustavsson MK, Zetterberg H et al (2012) Evaluation of the performance of novel Aβ isoforms as theragnostic markers in Alzheimer’s disease: from the cell to the patient. Neurodegener Dis 10:138–140
Portelius E, Price E, Brinkmalm G et al (2011) A novel pathway for amyloid precursor protein processing. Neurobiol Aging 32:1090–1098
Perrin RJ, Craig-Schapiro R, Malone JP et al (2011) Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer’s disease. PLoS One 6:e16032
Craig-Schapiro R, Kuhn M, Xiong C et al (2011) Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer’s disease diagnosis and prognosis. PLoS One 6:e18850
Craig-Schapiro R, Perrin RJ, Roe CM et al (2010) YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer’s disease. Biol Psychiatry 68:903–912
Portelius E, Dean RA, Gustavsson MK et al (2010) A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease. Alzheimers Res Ther 2:7
Albertini V, Bruno A, Paterlini A et al (2010) Optimization protocol for amyloid-β peptides detection in human cerebrospinal fluid using SELDI TOF MS. Proteomics Clin Appl 4:352–357
Portelius E, Brinkmalm G, Tran AJ et al (2009) Identification of novel APP/Abeta isoforms in human cerebrospinal fluid. Neurodegener Dis 6:87–94
Simonsen AH, McGuire J, Podust VN et al (2008) Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer’s disease. Neurobiol Aging 29:961–968
Simonsen AH, McGuire J, Hansson O et al (2007) Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol 64:366–370
Simonsen AH, McGuire J, Podust VN et al (2007) A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer’s disease versus normal aging and frontotemporal dementia. Dement Geriatr Cogn Disord 24:434–440
Finehout EJ, Franck Z, Choe LH et al (2007) Cerebrospinal fluid proteomic biomarkers for Alzheimer’s disease. Ann Neurol 61:120–129
Portelius E, Tran AJ, Andreasson U et al (2007) Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res 6:4433–4439
Hu Y, Hosseini A, Kauwe JS et al (2007) Identification and validation of novel CSF biomarkers for early stages of Alzheimer’s disease. Proteomics Clin Appl 1:1373–1384
Portelius E, Zetterberg H, Andreasson U et al (2006) An Alzheimer’s disease-specific beta amyloid fragment signature in cerebrospinal fluid. Neurosci Lett 409:215–219
Portelius E, Westman-Brinkmalm A, Zetterberg H et al (2006) Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation–mass spectrometry. J Proteome Res 5:1010–1016
Abdi F, Quinn JF, Jankovic J et al (2006) Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 9:293–348
Selle H, Lamerz J, Buerger K et al (2005) Identification of novel biomarker candidates by differential peptidomics analysis of cerebrospinal fluid in Alzheimer’s disease. Comb Chem High Throughput Screen 8:801–806
Zhang J, Goodlett DR, Quinn JF et al (2005) Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J Alzheimers Dis 7:125–133
Carrette O, Demalte I, Scherl A et al (2003) A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer’s disease. Proteomics 3:1486–1494
Puchades M, Hansson SF, Nilsson CL et al (2003) Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer’s disease. Brain Res Mol Brain Res 118:140–146
Davidsson P, Westman-Brinkmalm A, Nilsson CL et al (2002) Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport 13:611–615
Kiddle SJ, Steves CJ, Mehta M et al (2015) Plasma protein biomarkers of Alzheimer’s disease endophenotypes in asymptomatic older twins: early cognitive decline and regional brain volumes. Transl Psychiatry 5:e584. doi:10.1038/tp.2015.78
Muenchhoff J, Poljak A, Song F et al (2015) Plasma protein profiling of mild cognitive impairment and Alzheimer’s disease across two independent cohorts. J Alzheimers Dis 43:1355–1373
Zhao X, Lejnine S, Spond J et al (2015) A candidate plasma protein classifier to identify Alzheimer’s disease. J Alzheimers Dis 43:549–563
Yang H, Lyutvinskiy Y, Herukka SK et al (2014) Prognostic polypeptide blood plasma biomarkers of Alzheimer’s disease progression. J Alzheimers Dis 40:659–666
Song F, Poljak A, Kochan NA et al (2014) Plasma protein profiling of Mild Cognitive Impairment and Alzheimer’s disease using iTRAQ quantitative proteomics. Proteome Sci 12:5
Llano DA, Devanarayan V, Simon AJ (2013) Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease. Alzheimer Dis Assoc Disord 27:233–243
Guo LH, Alexopoulos P, Wagenpfeil S (2013) Plasma proteomics for the identification of Alzheimer disease. Alzheimer Dis Assoc Disord 27:337–342
Doecke JD, Laws SM, Faux NG et al (2012) Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol 69:1318–1325
Hu WT, Holtzman DM, Fagan AM et al (2012) Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 79:897–905
Soares HD, Potter WZ, Pickering E et al (2012) Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol 69:1310–1317
Johnstone D, Milward EA, Berretta R et al (2012) Multivariate protein signatures of pre-clinical Alzheimer’s disease in the Alzheimer’s disease neuroimaging initiative (ADNI) plasma proteome dataset. PLoS One 7:e34341
O’Bryant SE, Xiao G, Barber R et al (2011) A blood-based algorithm for the detection of Alzheimer’s disease. Dement Geriatr Cogn Disord 32:55–62
O’Bryant SE, Xiao G, Barber R et al (2011) A blood-based screening tool for Alzheimer’s disease that spans serum and plasma: findings from TARC and ADNI. PLoS One 6:e28092
O’Bryant SE, Xiao G, Barber R et al (2010) A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol 67:1077–1081
Ray S, Britschgi M, Herbert C et al (2007) Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins. Nat Med 13:1359–1362
Hye A, Lynham S, Thambisetty M et al (2006) Proteome-based plasma biomarkers for Alzheimer’s disease. Brain 129:3042–3050
Zhang J, Goodlett DR, Montine TJ (2005) Proteomic biomarker discovery in cerebrospinal fluid for neurodegenerative diseases. J Alzheimers Dis 8:377–386
Johanson CE, Duncan JA III, Klinge PM et al (2008) Multiplicity of cerebrospinal fluid functions: new challenges in health and disease. Cerebrospinal Fluid Res 5:10. doi:10.1186/1743-8454-5-10
Hokfelt T, Broberger C, Xu ZQ et al (2000) Neuropeptides—an overview. Neuropharmacology 39:1337–1356
Reiber H (2001) Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 310:173–186
Holtta M, Zetterberg H, Mirgorodskaya E et al (2012) Peptidome analysis of cerebrospinal fluid by LC–MALDI MS. PLoS One 7:e42555
De Almeida SM, Shumaker SD, Leblanc SK et al (2011) Incidence of post-dural puncture headache in research volunteers. Headache 51:1503–1510
Zetterberg H, Tullhög K, Hansson O et al (2010) Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients. Eur Neurol 63:326–330
Schneider P, Hampel H, Buerger K (2009) Biological marker candidates of Alzheimer’s disease in blood, plasma, and serum. CNS Neurosci Ther 15:358–374
Thambisetty M, Lovestone S (2010) Blood-based biomarkers of Alzheimer’s disease: challenging but feasible. Biomark Med 4:65–79
Lista S, Faltraco F, Hampel H (2013) Biological and methodical challenges of blood-based proteomics in the field of neurological research. Prog Neurobiol 101-102:18–34
Anderson NL, Anderson NG (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1:845–867
Gillette MA, Mani DR, Carr SA (2005) Place of pattern in proteomic biomarker discovery. J Proteome Res 4:1143–1154
Boschetti E, Lomas L, Citterio A et al (2007) Romancing the hidden proteome, Anno Domini two zero zero seven. J Chromatogr A 1153:277–290
Burtis CA, Ashwood E (eds) (2001) Tietz fundamentals of clinical chemistry. W.B. Saunders, Philadelphia, PA, USA
Apweiler R, Aslanidis C, Deufel T et al (2009) Approaching clinical proteomics: current state and future fields of application in fluid proteomics. Clin Chem Lab Med 47:724–744
Omenn GS, States DJ, Adamski M et al (2005) Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 5:3226–3245
Omenn GS (2011) Data management and data integration in the HUPO plasma proteome project. Methods Mol Biol 696:247–257
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.4